期刊
CELL HOST & MICROBE
卷 13, 期 3, 页码 250-262出版社
CELL PRESS
DOI: 10.1016/j.chom.2013.02.009
关键词
-
资金
- National Institutes of Health (NIH)/National Institute of Allergy and Infectious Diseases (NIAID) [AI-067665, AI-033774, AI-052733, AI-033142]
- National Heart, Lung, and Blood Institute (NHLBI) [HL-059842]
- Center for AIDS Research (CFAR) at the Albert Einstein College of Medicine [AI-51519]
- Aeras TB Vaccine Foundation
- Food and Drug Administration (FDA) [1U18 FD004012/01]
- Bill and Melinda Gates Grand Challenge award
- TB Vaccine Accelerator Program award
There is an urgent need for new and better vaccines against tuberculosis (TB). Current vaccine design strategies are generally focused on the enhancement of cell-mediated immunity. Antibody-based approaches are not being considered, mostly due to the paradigm that humoral immunity plays little role in the protection against intracellular pathogens. Here, we reappraise and update the increasing evidence for antibody-mediated immunity against Mycobacterium tuberculosis, discuss the complexity of antibody responses to mycobacteria, and address mechanism of protection. Based on these findings and discussions, we challenge the common belief that immunity against M. tuberculosis relies solely on cellular defense mechanisms, and posit that induction of antibody-mediated immunity should be included in TB vaccine development strategies.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据